ProQR Announces First Quarter 2023 Operating and Financial Results
16 mai 2023 07h00 HE
|
ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1Development of Axiomer® RNA base editing technology platform...
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
18 avr. 2023 08h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA...
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
29 mars 2023 08h00 HE
|
ProQR Therapeutics N.V.
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early...
ProQR Announces Third Quarter 2022 Operating and Financial Results
09 nov. 2022 07h00 HE
|
ProQR Therapeutics N.V.
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event...
ProQR Announces Webcast of Presentation at the Upcoming Stifel 2022 Healthcare Conference
03 nov. 2022 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- LEIDEN, Netherlands & CAMBRIDGE, Mass., November 3, 2022 -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”),...
ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs
11 août 2022 07h00 HE
|
ProQR Therapeutics N.V.
In line with corporate strategy update in April, ProQR to focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas; update on initial...
ProQR Announces Second Quarter 2022 Operating and Financial Results
04 août 2022 07h00 HE
|
ProQR Therapeutics N.V.
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022Company plans to...
ProQR to Participate in the Kempen Life Sciences Conference
19 avr. 2022 16h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR to Present Axiomer RNA Editing Platform Technology at RNA Editing Summit
04 avr. 2022 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...
ProQR Appoints John Maraganore, PhD, as Strategic Advisor to the Supervisory Board
07 mars 2022 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of...